TPO and autoimmune thrombocytopenic purpura: The experts concurred that TPO-RAs plus glucocorticoids could provide a promising first-line therapy with a dual action (i.e., immunosuppression and stimulation of platelet production) with the potential to decrease corticosteroid exposure for a significant number of ITP adults.